Healthcare Industry News: Terumo
News Release - September 12, 2007
Proven Terumo Coronary Guidewire Technology Is Now Available in the United StatesSOMERSET, N.J., Sept. 12 (HSMN NewsFeed) -- Having already made great strides in Japan and Europe, Terumo's Runthrough NS Coronary Guidewire is ready to take on America. Terumo Interventional Systems announces the launch of its breakthrough Runthrough(TM) NS Coronary Guidewire to the U.S. market. With its superior tip durability, complete torque transfer and enhanced steerability, this coronary guidewire boasts efficiency and reliability unlike that of other coronary guidewires. For use in percutaneous transluminal coronary angioplasties (PTCA), this product launch expands Terumo's expertise beyond the periphery and into the coronary space.
The primary difference between the Runthrough NS and other coronary guidewires is its exceptional tip shape retention. Because the tip retains its shape better than the leading coronary guidewires, as shown in head-to-head testing, the Runthrough NS gives physicians the ability to perform multi-vessel procedures with one wire. By making vessel selection and lesion crossing easier, the Runthrough NS may result in more efficient and cost-effective procedures.
"The tip is worth its weight in gold," said Dr. Richard Heuser, Chief of Cardiology with St. Luke's Medical Center, Phoenix, Arizona, who was involved in the U.S. trials of the Runthrough NS.
The Runthrough NS also features Terumo's unique DuoCore(TM) Technology. DuoCore fuses two proven guidewire technologies for one-to-one torque transfer and ensures excellent steerability, pushability and trackability. The fine tactile feel of the Runthrough NS also provides excellent guide and device support.
In addition, this first-choice coronary guidewire features the optimal balance of hydrophobic and hydrophilic coatings. The resultant smooth trackability in tortuous vessels and superior device delivery creates a significantly improved experience for the user.
"The balloon feels as if it is floating down the wire with absolutely no resistance," commented Dr. Lee Jobe of Wake Heart after testing the Runthrough NS.
"The launch of our first coronary product in the United States is very exciting," said Gary Clifton, Marketing Manager, Terumo Interventional Systems Coronary Product Line. "But more than that, to have a product received so well by the Cardiology community is a true testament to our heritage of product innovation."
For more information, customers can contact Terumo Interventional Systems by calling its Inside Sales Customer Care Team at 800-862-4143 or by visiting http://www.terumomedical.com/interventional.
Terumo Interventional Systems
Terumo Interventional Systems (TIS), a strategic business unit of Terumo Medical Corporation, directly markets a full line of guidewires, catheters, introducer sheaths, guiding sheaths and embolization products for use in a multitude of different interventional procedures.
Interventional Radiologists, Interventional Neuroradiologists, Interventional Cardiologists and Vascular Surgeons are among the medical professionals who depend upon TIS products to access and cross difficult-to- reach lesions thereby allowing therapeutic intervention in previously unreachable vascular beds.
Terumo Medical Corporation
Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets. TMC manufactures a broad portfolio of needles and syringes, entry-site management products, and a line of sterile connection devices used in hospitals and blood banks worldwide.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $2.3 billion in sales and operations in more than 150 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543:JP) and is a component of the Nikkei 225, Japan's leading stock index.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.